Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout

Catalent (CTLT.N) CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk (NOVOb.CO).